Peer-Reviewed Papers & Conference Presentations
Meso-tetra (4-carboMeso-tetra (4-carboxyphenyl) Porphyrin (TCPP) is taken up in Cancer Cells by the CD320 Receptor
Simultaneous knockdown of CD320 and LRP2 receptors is selectively toxic to cancer cells but not normal cells
Identification of a novel mechanism for meso‐tetra (4‐carboxyphenyl) porphyrin (TCPP) uptake in cancer cells
Automated Flow Cytometry Test Distinguishes Cancer from Non-Cancer in Sputum with High Sensitivity and Specificity
Meso-tetra (4-carboxyphenyl) porphyrin (TCPP) is incorporated into cancer cells by the CD320 receptor and clathrin mediated endocytosis
Porphyrin uptake in lung cancer cells by dynamin-mediated endocytosis: a novel marker of dysregulated endocytosis in cancer
bioAffinity's Diagnostics Efforts
CyPath® uses a porphyrin molecule that displays an unusually high affinity to bind to cancer cells that fluoresce brightly when labeled to distinguish cancer from non-cancer cells using flow cytometry.
Our innovative scientific research is aimed at developing non-invasive diagnostics for various cancers and other lung diseases. Our first test, CyPath® Lung, is available through Precision Pathology Services to physicians for their patients at high risk for lung cancer.
This animated video produced by the Massachusetts Institute of Technology (MIT) Star CellBio introduces flow cytometry, a technique in which cells are suspended in a fluid and flow one at a time through a focus of exciting light, which is scattered in patterns characteristic to the cells and their components.
Cells are labeled with fluorescent markers so that light is first absorbed and then emitted at altered frequencies. A sensor detecting the emitted light measures the size and molecular characteristics of individual cells. Millions of cells can be examined in minutes and the resulting data is analyzed by computer. A picture of the lung environment is revealed by analyzing the cell populations in a sample to determine if a disease is present.
bioAffinity's Therapeutics Efforts
Through our subsidiary, OncoSelect® Therapeutics, our company focuses on advancing discoveries related to broad-spectrum cancer therapeutics. In researching porphyrins’ selectivity for cancer, we discovered novel therapies that kill cancer cells without harm to normal cells in vitro.
We will continue with animal studies to advance our discoveries. Our research also looks to attach cancer-killing cytotoxic drugs to porphyrins, a cancer-selective molecule that is taken up by tumors in much greater amounts than by non-cancer tissue.
Animation of a Porphyrin molecule